Latest Content

The agency concluded that GLP-1 receptor agonists carry a potential increased risk of the rare optic neuropathy and is adding it to the Warnings and Precautions section of every product's label.

More consumers spent $100 to $199 on eyewear in Q3 2026, and managed vision care coverage reached a 5-quarter high of 72%.

As artificial intelligence advances, so do VR devices.

A wet AMD biosimilar approval leads this week’s recap, plus Medicare pay updates and tips to avoid burnout and losing patients.

MyoSpectrumNet pulls 3 public fundus datasets into 1 multi-output framework. Screening and grading accuracy held up against dedicated models.

ODs face a $32.63 Medicare conversion factor in 2027, plus 80% payment for the lower-cost service when an E/M visit and 0-day procedure share a date.

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

Christopher Browning, OD, and Nicholas Garn, OD, now offer cataract surgery and refractive lens exchange in their own practices.

According to Raphael Rostenne, CTO of EyeCarePro, "anything that takes time" has the potential to frustrate patients, especially before they're in a practitioner's chair.

Kansas, Tennessee, and Vermont expanded optometric scope in 2026, while vision plan reform and a proposed Medicare fee schedule cut affect practice management.

Bita Asghari, OD, FAAO, FSLS, discusses diagnosing ocular surface inflammation, recognizing atypical keratitis, and knowing when to refer to a cornea specialist.

The approval followed complete response letters tied to inspection and manufacturing issues.

What to take away on PBM, hormonal eye health, and GLP-1 receptor agonists from this year’s meeting.